MaxCyte agrees to acquire Akron BioProducts for $151.8 million

This is a valid forward-looking merger and acquisition development: MaxCyte entered a definitive agreement to acquire Akron BioProducts for $151.8 million, with cash, newly issued shares, and deferred payments, and expects the acquisition to nearly double its revenue base. The direct wire report and corroborating source support the parties, consideration, strategic rationale, and pending status. The transaction’s concurrent financing and dilution are relevant terms of the acquisition but do not change the central development type from merger_acquisition. November 10, 2026 is explicitly supported; 11:00 UTC is estimated from the wire timestamp rather than independently stated as the exact announcement time. MXCT is the direct approved stakeholder, while RGEN is included as a clearly exposed cell-therapy consumables competitor; more distant ecosystem companies are excluded due to weaker event-specific support. The prior new-event classification is retained because no existing-event context is available to justify changing it.